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Abstract
It is important to treat patients with Cushing’s disease as rapidly as possible to limit its long-term
mortality and morbidity. Selective transphenoidal pituitary adenomectomy remains the treatment of
choice but, unfortunately, the rate of cure at long-term follow-up is suboptimal and recurrences are
high, even in the hands of expert neurosurgeons. Treatment options for persistent or relapsed
disease include repeat trasphenoidal pituitary surgery, radiotherapy or bilateral adrenalectomy.
Medical treatment, a second-line treatment option, may have either a primary or adjunctive role if the
patient cannot safely undergo surgery, if surgery fails, or if the tumor recurs. Cabergoline and
pasireotide (SOM230), two pituitary tumor-directed drugs, are the most exciting news in the
human pharmacological approach. However, the use of these drugs in clinical practice and their real
impact in the management of patients is yet to be determined. The treatment of patients with
Cushing’s disease is complex and requires a multidisciplinary and individualized approach to patient
management using cost-benefit analyses.
Introduction and context
Cushing’s disease (CD) results from a chronic excess of
cortisol secretion caused by a adrenocorticotropic
hormone (ACTH)-secreting pituitary adenoma [1,2].
The goal of treatment is the complete surgical removal
of corticotroph tumors. Selective transphenoidal pitui-
tary adenomectomy remains the treatment of choice for
CD but, unfortunately, the rate of cure at long-term
follow-up is suboptimal and recurrences are high, even
in the hands of expert neurosurgeons [3]. Immediate
remission rates range from 65-90%, with recurrence
rates reaching about 25% after 10 years [4-8]. Remission
rates are lower and recurrence rates higher in patients
with macroadenomas and in patients with cavernous
sinus or dura invasion.
The use of endoscopic surgery is of interest but a
comparison on outcome between microscopic and
endoscopic techniques cannot be made [3]. Treatment
options for persistent or relapsed CD include repeat
trasphenoidal pituitary surgery, radiotherapy or bilateral
adrenalectomy. In specialized centers, repeat pituitary
surgery has been shown to be efficacious in approxi-
mately 50-70% of patients, especially if an adenoma
was identified at the first surgery [3,9,10]. However,
a second pituitary surgery carries increased risk of
hypopituitarism, particularly when a more extensive
surgical excision has been performed.
Radiation therapy (conventional or stereotactic radio-
surgery) should be reserved for second- or third-line
treatment; it results in remission in approximately 60%
of patients within 3-5 years [3,11-13]. The main
drawbacks of radiotherapy include long time-to-effect
and risk of delayed hypopituitarism (in up to 70% of
patients). The possible causative link between radiation
therapy and cerebrovascular events and neurocognitive
dysfunctions is still unclear. The incidence of hypopitui-
tarism appears to be similar between different types of
radiotherapy [11-13]. At present, there are insufficient
data to determine whether radiosurgery has a more
rapid effect than conventional radiation therapy and
whether any particular radiotherapeutic technique is
preferable [3].
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mally invasive laparoscopic technique, provides an
immediate final cure in cases where other treatments
fail [3,14-16]. However, apart from surgical risks, this
treatment requires lifelong glucocorticoid and miner-
alocorticoid-replacement therapy (which is often sub-
optimal) and carries with it the risk of Nelson’s
syndrome, the prevalence of which ranges from 8-29%
[17].
According to the recent consensus conference, medical
therapy represents a second-line treatment in patients
with persistent or recurrent disease as well as in
patients treated with radiotherapy in whom the bene-
ficial effects are delayed, prior to adrenalectomy and
in all patients not suitable for surgery [3]. Of note,
additional medical therapy may be useful in patients
undergoing pituitary surgery (especially in the presence
of diabetes, hypertension, and marked coagulation
abnormalities).
Many drugs have been tentatively employed in the
treatment of CD but none has been proven fully
satisfactory. These may act at the hypothalamic-pituitary
level and decrease ACTH secretion, at the adrenal level,
inhibiting cortisol synthesis (steroidogenesis inhibitors),
or at the peripheral level by competing with cortisol
(glucocorticoid receptor antagonist) [3].
Recent advances
There is controversy regarding the definition of apparent
cure after surgery for CD, and remission rates vary
according to the criteria used and the time of assessment
[1,3]. The definition of cure and the prognostic effect of
subtle or unrecognized residual hypercortisolism have a
major clinical impact on the follow-up and therapeutic
decisions for patients. Recently, a consensus statement
recommended the measurement of morning cortisol
during the first postoperative week: hypoadrenalism
(serum cortisol below 2 µg/dl) is probably the best index
of remission, but even when this is the case, late relapses
may occur. When serum cortisol is between 2 and 5 µg/dl
the patient can be considered in remission, whereas
serum cortisol above 5 µg/dl for up to 6 weeks is
indicative of persistent disease and requires further
evaluation [1,3]. It is noteworthy that no single test can
rule out the possibility of future recurrence after surgery
so patients should be followed up for many years. The
measurement of cortisol in saliva, a useful screening test
for hypercortisolism, could have some advantages: it is
easy to perform at home and is noninvasive [18,19].
A recent study suggested that measurement of midnight
salivary cortisol can be a very good marker for predicting
remission and future relapse [20]. However, further and
larger studies are needed to confirm this interesting
finding considering that, using various assays, a strict
standardization of both collection and analysis methods
is necessary and normal reference ranges and diagnostic
cut-offs should be validated in each laboratory before
being applied to a large population [18].
The treatment of CD is very complex and represents
a challenge for clinicians, requiring a multidisciplinary
and individualized approach to patient management
using cost-benefit analyses. In the case of failure after
surgery or relapse (late relapses have been reported at
20 years after surgery) no treatment has proven to be
fully satisfactory during the lengthy progression of this
chronic and devastating disease. According to the recent
consensus conference, the treatment recommendation
may, in part, depend on the treatment option available
as well as the acceptability of the relative risks. In general,
experts favor repeat pituitary surgery as the initial therapy
for persistent or recurrent disease, then radiotherapy
(conventional or radiosurgery) if this is unsuccessful [3].
So far, medical therapy has been considered a transient
and palliative treatment. However, recently there has been
renewed interest in this topic due to new insights into the
pathogeneticmechanismsofcorticotrophtumors[21-23].
Cabergoline and pasireotide (SOM230), two pituitary
tumor-directed drugs, are the most exciting news in the
pharmacological approach to human CD [3,24].
Recently, Pivonello et al. [25] evaluated long-term
efficacy and safety in 20 patients with persistent
CD during long-term treatment with cabergoline. At
24-month follow-up, eight (40%) patients were persis-
tently controlled at a median cabergoline dose of
3.5 mg/week. In addition, the clinical picture improved
during treatment and significant tumor shrinkage was
observed in 20% of patients [25].
Pasireotide exhibits a unique profile with high affinity
for four of the five somatostatin receptors (ssts),
especially sst type 5, which is the most prevalent sst in
corticotroph tumors [22-24,26,27]. In a recent phase II
open-label single-arm multicenter study, 39 patients
with de novo persistent or recurrent CD were treated with
pasireotide 600 mcg subcutaneously twice daily for
15 days [28]. Of the 29 patients included in the primary
efficacy population, 22 patients (76%) showed a
reduction of 24-hour urinary free cortisol, of which
5 (17%) had normalized 24-hour urinary free cortisol
(responders). Overall, the mean 24-hour urinary free
cortisol level decreased from baseline by 44.5% at the
end of the short period of treatment. Worsening of
glucose metabolism (14 patients with hyperglycemia)
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generally, was transient. Pharmacokinetic analysis
showed that a steady-state plasma concentration was
achieved within 5 days. Responders appeared to have
higher pasireotide exposure than non-responders.
Currently, the most exciting news with regard to
pharmacological approaches to human CD is the efficacy
of cabergoline and pasireotide; however, prolonged
treatment and more data will be needed to evaluate
their long-term therapeutic efficacy and safety.
Implications for clinical practice
It is important to treat CD as rapidly as possible to limit
its long-term mortality and morbidity. In the case of
failure of pituitary surgery no treatment has been proven
fully satisfactory. There is controversy regarding the
definition of apparent cure after surgery. Early identifica-
tion of patients with persistent or recurrent disease is very
important to minimize the effects of subtle or unrecog-
nized residual hypercortisolism. Midnight salivary
cortisol, a useful screening test for diagnosing hypercor-
tisolism, could be a very good marker for predicting
remission and future relapse. Medical treatment, a
second-line treatment option, may have either a primary
or adjunctive role if the patient cannot safely undergo
surgery, if surgery fails, or if the tumor recurs. The use of
cabergoline and pasireotide in clinical practice and their
real impact in the management of patients with CD are
yet to be determined.
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